Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Zeitschrift für Rheumatologie (Print)

• Publication date

  2018-05-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s00393-016-0254-4PMID 28097393
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rheumatoid arthritis

  2016cited by this paper
• Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.

  2016cited by this paper
• Baricitinib for the treatment of rheumatoid arthritis

  2016cited by this paper
• SAT0177 Baricitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

  2016cited by this paper
• Baricitinib in Patients with Refractory Rheumatoid Arthritis.

  2016cited by this paper
• Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study

  2016cited by this paper
• Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study

  2015cited by this paper
• LB0001 Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and An Inadequate Response to CDMARD Therapy: Results of the Phase 3 RA-Build Study

  2015cited by this paper
• Selective JAK inhibitors in development for rheumatoid arthritis

  2014cited by this paper
• The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers

  2014influential reference
• Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

  2014cited by this paper
• Network meta-analysis for comparing treatment effects of multiple interventions: an introduction

  2014cited by this paper
• A Microsoft-Excel-based tool for running and critically appraising network meta-analyses—an overview and application of NetMetaXL

  2014cited by this paper
• Evidence Synthesis for Decision Making Inconsistency in Networks of Evidence Based on Randomized Controlled Trials.

  2013cited by this paper
• Evidence Synthesis for Decision Making 4

  2013cited by this paper
• The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells

  2013cited by this paper
• Automating network meta‐analysis

  2012cited by this paper
• Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies

  2012cited by this paper
• Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial.

  2011cited by this paper
• Janus kinases in immune cell signaling

  2009cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.

  2008cited by this paper
• JAK-STAT Signaling: From Interferons to Cytokines*

  2007cited by this paper
• Simultaneous comparison of multiple treatments: combining direct and indirect evidence

  2005cited by this paper
• Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines

  2005cited by this paper
• The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis.

  1992cited by this paper

• Treatment of active systemic lupus erythematosus with baricitinib: A meta-analysis of randomized controlled trials

  2023cites this paper
• Baricitinib retention rate: ‘real-life’ data from a mono-centric cohort of patients affected by rheumatoid arthritis

  2023cites this paper
• Efficacy and safety of different doses of baricitinib for rheumatoid arthritis: A Bayesian network meta-analysis

  2022cites this paper
• JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis

  2021cites this paper
• Janus Kinase Inhibitors and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis.

  2021cites this paper
• BARICITINIB: NEW PHARMACOTHERAPY OPTIONS FOR RHEUMATOID ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES

  2020cites this paper
• Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis

  2020cites this paper
• Optimising Response to Advanced Therapies in Rheumatoid Arthritis – Using Prehabilitation to Improve Success?

  2020cites this paper
• Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials

  2019cites this paper
• Safety of baricitinib in East Asian patients with moderate‐to‐severe active rheumatoid arthritis: An integrated analysis from clinical trials

  2019cites this paper
• Comparative efficacy and safety of 15 and 30 mg upadacitinib administered to patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials

  2019cites this paper
• Baricitinib: A Review in Rheumatoid Arthritis

  2018cites this paper
• Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials

  2018cites this paper
• Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?

  2018cites this paper